Pioneering diagnostics


For more than 30 years, bioMérieux has been developing a range of AIDS diagnostic tests to improve the care of patients living with HIV.

The human immunodeficiency virus (HIV) infects the cells of the immune system and destroys them or makes them ineffective. This results in the gradual deterioration of the immune system, which can no longer fight infection.

The term "AIDS" applies to the more advanced stages of HIV infection, defined by the development of one or several of the  opportunistic infections or cancers associated with HIV.

The healthcare challenge

According to 2016 data from UNAIDS, in the world in 2015:

  • 36.7 million people were living with HIV;
  • 18.2 million people were receiving antiretroviral treatment;
  • 2.1 million people became newly infected with HIV;
  • 1.1 million people died from AIDS-related illnesses.

In the fight against AIDS, the WHO has set new objectives aiming to reach the 90-90-90 target established by UNAIDS by 2020:

  • 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy;
  • 90% of all people living with HIV will know their HIV status;
  • 90% of all people receiving antiretroviral therapy will have sustained viral suppression.

The role of in vitro diagnostics

Screening tests play a decisive role in successfully reaching this 90-90-90 target: early detection means patients can receive the best possible care to prevent the spread of the virus. 

For more than 30 years, bioMérieux has been at the cutting edge of innovation in the fight against AIDS. The Company developed one of the first screening tests in 1985. Since then our researchers’ efforts have culminated in the development of one of the broadest ranges of high-performance tests available for the diagnosis and monitoring of HIV infection, meeting the needs of patients and physicians. 

The tests detect antibodies directed towards the HIV and/or the p24 antigen in the patients' blood, thus allowing the infection to be diagnosed earlier. bioMérieux also offers a molecular biology test for viral load monitoring. It is used to follow changes in the patient's disease before and after starting treatment, so that the most appropriate therapy can be prescribed and any resistance to treatment will be rapidly detected.


 bioMérieux and the access to innovative screening techniques 

bioMérieux is committed to making the latest innovations in HIV screening available to all types of healthcare settings and systems. We were the first company to develop a CE-approved protocol on filter paper for viral load monitoring, ideally suited for remote areas with limited resources. The Dry Blood Spot technique consists of depositing a blood sample on filter paper, with no need for refrigeration. Samples may be taken in local dispensaries, with no need for a laboratory or qualified technicians. 

30 years of innovation in fighting HIV/AIDS

  • 1985: VIRONOSTIKA® anti-HTLV III
    First screening tests available
  • 1987: VIRONOSTIKA HIV Uni-Form
    One-step microElisa assay
  • 1988: VIRONOSTIKA HIV-1 Antigen
    P24 antigen detection
    HIV-1 and HIV-2 detection
  • 1991: VIDAS® HIV-1+2
    First automated HIV assay
  • 1992: VIRONOSTIKA HIV Uni-Form II
    3rd generation microplate test
  • 1993: VIDAS HIV-1 anti p24
    First automated HIV-1 p24 Ab test
  • 1993: NucliSENS® HIV-1 QL
    Qualitative HIV-1 RNA
  • 1994: VIDAS HIV p24 Ag
    Quantitative Ag detection in automated format
  • 1995: VIRONOSTIKA HIV Uni-Form II plus O
    Group O detection
  • 1995: NASBA HIV-1 QT
    First HIV-1 viral load assay
  • 1998: VIDAS HIV DUO
    First 4th generation automated test
  • 1998: VIRONOSTIKA HIV Uni-Form II Ag/Ab
    First 4th generation microplate test
  • 2002: NucliSENS EasyQ® HIV-1
    First real-time HIV-1 viral load assay
  • 2004: VIDAS HIV DUO Ultra / VIDAS HIV DUO Quick
    Advanced 4th generation automated tests
  • 2007: VIKIA® HIV 1/2
    Simple hand-held device for rapid testing
  • 2009: NucliSENS Easy Q® HIV-1 v2.0
    Real-time HIV-1 viral load assay on plasma
    and Dry Blood Spot
  • 2011: NucliSENS Easy Q®HIV-1 v2.0
    WHO prequalification
  • 2013: VIKIA® HIV 1/2
    WHO prequalification